Invst LLC Makes New Investment in DaVita Inc. $DVA

Invst LLC acquired a new position in DaVita Inc. (NYSE:DVA) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 5,564 shares of the company’s stock, valued at approximately $1,238,000.

Several other large investors have also added to or reduced their stakes in the business. Root Financial Partners LLC grew its position in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after buying an additional 105 shares during the period. Caitlin John LLC acquired a new position in shares of DaVita during the 4th quarter valued at $34,000. Sankala Group LLC acquired a new position in shares of DaVita during the 4th quarter valued at $39,000. Canada Pension Plan Investment Board bought a new position in DaVita during the second quarter worth $43,000. Finally, Kestra Advisory Services LLC acquired a new stake in DaVita in the fourth quarter worth $45,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

NYSE:DVA opened at $177.84 on Wednesday. DaVita Inc. has a one year low of $101.00 and a one year high of $247.49. The company has a market cap of $11.35 billion, a PE ratio of 14.55, a PEG ratio of 0.59 and a beta of 0.88. The firm has a 50-day moving average of $213.68 and a 200-day moving average of $182.58.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts expect that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on DVA shares. UBS Group lifted their price target on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Barclays boosted their target price on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Truist Financial cut their price target on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Finally, Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, DaVita currently has an average rating of “Hold” and an average target price of $221.75.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.90% of the stock is owned by corporate insiders.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.